| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.94▼ | 0.94▼ | 0.94▼ | 1.06▼ | 1.08▼ |
| MA10 | 0.95▼ | 0.97▼ | 0.98▼ | 1.12▼ | 1.17▼ |
| MA20 | 0.99▼ | 1.02▼ | 1.04▼ | 1.14▼ | 1.26▼ |
| MA50 | 1.05▼ | 1.09▼ | 1.11▼ | 1.25▼ | 1.30▼ |
| MA100 | 1.10▼ | 1.13▼ | 1.14▼ | 1.31▼ | 1.28▼ |
| MA200 | 1.14▼ | 1.16▼ | 1.19▼ | 1.35▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.007▼ | -0.011▼ | -0.015▼ | -0.040▼ |
| RSI | 21.968▼ | 21.716▼ | 23.765▼ | 26.841▼ | 36.117▼ |
| STOCH | 8.282▼ | 3.312▼ | 2.563▼ | 19.074▼ | 7.947▼ |
| WILL %R | -88.299▼ | -90.608▼ | -92.861▼ | -95.492▼ | -97.651▼ |
| CCI | -86.336 | -94.188 | -98.720 | -216.312▼ | -190.228▼ |
|
Friday, March 27, 2026 03:27 AM
Vivani Medical (Nasdaq:VANI) announced the successful completion of the first-in-human study of its GLP-1 implant.
|
|
Thursday, March 26, 2026 02:07 PM
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under ...
|
|
Sunday, January 25, 2026 11:40 PM
(RTTNews) - Vivani Medical, Inc. (VANI), a clinical-stage biopharmaceutical company, has offered to sell 1.69 million shares of common stock at $1.48 per share in a registered direct offering, along ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/03/26 | 1.03 | 1.05 | 0.9228 | 0.938 | 435,564 |
| 27/03/26 | 1.06 | 1.06 | 1.015 | 1.02 | 241,906 |
| 26/03/26 | 1.10 | 1.11 | 1.065 | 1.08 | 270,209 |
| 25/03/26 | 1.13 | 1.14 | 1.12 | 1.13 | 84,496 |
| 24/03/26 | 1.17 | 1.17 | 1.12 | 1.12 | 149,569 |
| 23/03/26 | 1.18 | 1.24 | 1.1656 | 1.18 | 148,204 |
| 20/03/26 | 1.15 | 1.22 | 1.11 | 1.16 | 739,915 |
| 19/03/26 | 1.15 | 1.1778 | 1.11 | 1.15 | 220,599 |
| 18/03/26 | 1.24 | 1.24 | 1.15 | 1.17 | 101,277 |
| 17/03/26 | 1.23 | 1.25 | 1.21 | 1.21 | 279,300 |
|
|
||||
|
|
||||
|
|